Related Experiment Video
Updated: Feb 17, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Possible drug reaction with eosinophilia and systemic symptoms after spironolactone therapy for clinical
Sandy Hoang1, Danielle Strom1, Kathleen M Brennan1
1Department of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, California.
Objective:
To present a case of possible drug reaction with eosinophilia and systemic symptoms (DRESS) after spironolactone and to review existing literature on serious cutaneous adverse reactions to spironolactone.
Design:
Case report and literature review.
Subject:
A 29-year-old woman with hyperandrogenism who developed a febrile, pruritic, generalized rash 1 week after initiating spironolactone.
Exposure:
Discontinuation of spironolactone.
Main Outcome Measures:
Resolution of symptoms, RegiSCAR diagnostic assessment for DRESS.
Results:
Symptoms resolved after discontinuation and recurred upon two separate rechallenges. Although laboratory and histopathological data were not available to definitively confirm the diagnosis of DRESS, clinical features were suspicious for DRESS on the basis of RegiSCAR criteria. The patient met five diagnostic criteria, which would classify this as a "possible" case. Other reported cutaneous reactions to spironolactone include linear immunoglobulin A bullous dermatosis and erythema multiforme.
Conclusion:
Clinicians should be aware of the rare but potentially serious risk of DRESS in patients treated with spironolactone. Prompt recognition, drug discontinuation, and supportive management are essential. Diagnostic confirmation with laboratory studies and skin biopsy should be pursued in suspected cases.
More Related Videos
Related Concept Videos
Allergic Reactions
Drug Toxicity: Allergic Reactions
Allergic Reactions: Anaphylaxis
Allergic Drug Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

